JP2004504376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504376A5 JP2004504376A5 JP2002514087A JP2002514087A JP2004504376A5 JP 2004504376 A5 JP2004504376 A5 JP 2004504376A5 JP 2002514087 A JP2002514087 A JP 2002514087A JP 2002514087 A JP2002514087 A JP 2002514087A JP 2004504376 A5 JP2004504376 A5 JP 2004504376A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- ht2c
- pharmaceutical composition
- antagonist
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 10
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 9
- 239000000018 receptor agonist Substances 0.000 description 7
- 229940044601 receptor agonist Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 108091005435 5-HT6 receptors Proteins 0.000 description 5
- 239000003751 serotonin 6 antagonist Substances 0.000 description 5
- 229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 101150104779 HTR2A gene Proteins 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 101150075901 htr2 gene Proteins 0.000 description 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 1
- PBIZLLBVGQBNJU-UHFFFAOYSA-N C1CC2=NC=CC=CC2=C2C1CCN2 Chemical class C1CC2=NC=CC=CC2=C2C1CCN2 PBIZLLBVGQBNJU-UHFFFAOYSA-N 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- -1 piperazinylpyrazine compound Chemical class 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- ISZIQZCZKOFSBT-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepine Chemical group N1=CC=CC=C2C3=NC=CC3=CC=C21 ISZIQZCZKOFSBT-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0002754A SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | New pharmaceutical combination formulation and method of treatment with the combination |
| PCT/SE2001/001651 WO2002008178A1 (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004504376A JP2004504376A (ja) | 2004-02-12 |
| JP2004504376A5 true JP2004504376A5 (sh) | 2008-07-17 |
Family
ID=20280577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002514087A Withdrawn JP2004504376A (ja) | 2000-07-21 | 2001-07-19 | 医薬製剤としてのセロトニンアゴニスト（５ｈｔ２）とアンタゴニスト（５ｈｔ６）の新規組み合わせ |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1301476A1 (sh) |
| JP (1) | JP2004504376A (sh) |
| KR (1) | KR100845450B1 (sh) |
| CN (1) | CN1221254C (sh) |
| AU (2) | AU8273401A (sh) |
| BR (1) | BR0112661A (sh) |
| CA (1) | CA2411192A1 (sh) |
| EA (1) | EA006604B1 (sh) |
| HK (1) | HK1057536A1 (sh) |
| HU (1) | HUP0301346A3 (sh) |
| IL (1) | IL154057A0 (sh) |
| MX (1) | MXPA03000548A (sh) |
| NO (1) | NO20030304L (sh) |
| NZ (1) | NZ523216A (sh) |
| PL (1) | PL360309A1 (sh) |
| SE (1) | SE0002754D0 (sh) |
| WO (1) | WO2002008178A1 (sh) |
| YU (1) | YU2603A (sh) |
| ZA (1) | ZA200210234B (sh) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| JP4184077B2 (ja) * | 2000-11-02 | 2008-11-19 | ワイス | ５−ヒドロキシトリプトアミン−６リガンドとしての１−アリールまたは１−アルキルスルホニル−ヘテロシクリルベンザゾール |
| KR20040010709A (ko) * | 2001-06-15 | 2004-01-31 | 에프. 호프만-라 로슈 아게 | 5-ｈｔ6 수용체 친화력을 갖는 4-피페라지닐인돌 유도체 |
| CN1321110C (zh) * | 2001-06-15 | 2007-06-13 | 弗·哈夫曼-拉罗切有限公司 | 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物 |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| MXPA04009318A (es) | 2002-03-27 | 2005-01-25 | Glaxo Group Ltd | Derivados de quinolina y su uso como ligados 5-ht6. |
| CL2004000826A1 (es) * | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
| EP2248524A3 (en) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| WO2007076875A2 (en) * | 2006-01-06 | 2007-07-12 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| US8158617B2 (en) | 2006-05-16 | 2012-04-17 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| WO2007149728A2 (en) * | 2006-06-20 | 2007-12-27 | Alcon Research, Ltd. | Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
| ATE495737T1 (de) * | 2007-08-01 | 2011-02-15 | Esteve Labor Dr | Kombination von mindestens zwei 5-ht6-liganden |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| UA100192C2 (en) | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
| JP5579262B2 (ja) | 2009-06-15 | 2014-08-27 | 武田薬品工業株式会社 | ピラジノオキサゼピン誘導体 |
| JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| MX2017016413A (es) | 2015-06-12 | 2018-08-01 | Axovant Sciences Gmbh | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem. |
| JP2018520187A (ja) | 2015-07-15 | 2018-07-26 | アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH | 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体 |
| CN107628981B (zh) * | 2017-10-31 | 2019-07-30 | 威海市妇女儿童医院 | 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用 |
| JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
| CN111269165A (zh) * | 2018-12-05 | 2020-06-12 | 中国科学院大连化学物理研究所 | 一种3-芳基磺酰基吲哚衍生物的合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| GB9819035D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
-
2000
- 2000-07-21 SE SE0002754A patent/SE0002754D0/xx unknown
-
2001
- 2001-07-19 CA CA002411192A patent/CA2411192A1/en not_active Abandoned
- 2001-07-19 JP JP2002514087A patent/JP2004504376A/ja not_active Withdrawn
- 2001-07-19 AU AU8273401A patent/AU8273401A/xx active Pending
- 2001-07-19 HU HU0301346A patent/HUP0301346A3/hu unknown
- 2001-07-19 WO PCT/SE2001/001651 patent/WO2002008178A1/en active IP Right Grant
- 2001-07-19 CN CNB018131549A patent/CN1221254C/zh not_active Expired - Fee Related
- 2001-07-19 NZ NZ523216A patent/NZ523216A/en not_active IP Right Cessation
- 2001-07-19 YU YU2603A patent/YU2603A/sh unknown
- 2001-07-19 EP EP01961472A patent/EP1301476A1/en not_active Withdrawn
- 2001-07-19 PL PL36030901A patent/PL360309A1/xx not_active Application Discontinuation
- 2001-07-19 BR BR0112661-0A patent/BR0112661A/pt not_active IP Right Cessation
- 2001-07-19 AU AU2001282734A patent/AU2001282734B2/en not_active Ceased
- 2001-07-19 EA EA200300183A patent/EA006604B1/ru not_active IP Right Cessation
- 2001-07-19 MX MXPA03000548A patent/MXPA03000548A/es active IP Right Grant
- 2001-07-19 IL IL15405701A patent/IL154057A0/xx unknown
- 2001-07-19 KR KR1020037000321A patent/KR100845450B1/ko not_active IP Right Cessation
-
2002
- 2002-12-18 ZA ZA200210234A patent/ZA200210234B/en unknown
-
2003
- 2003-01-20 NO NO20030304A patent/NO20030304L/no not_active Application Discontinuation
-
2004
- 2004-01-15 HK HK04100306A patent/HK1057536A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004504376A5 (sh) | ||
| AU2006252051B2 (en) | Orodispersible Pharmaceutical Composition for Oromucosal or Sublingual Administration of Agomelatine | |
| HUP0301346A2 (hu) | Szterotonin agonista (5HT2) és antagonista (5HT6) új kombinációja gyógyászati készítményként és eljárás az előállítására | |
| CA2229597A1 (en) | Oral fast-dissolving compositions for dopamine agonists | |
| AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
| RU2005124363A (ru) | Твердые пероральные дозируемые формы валсартана | |
| WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| JP2008531714A (ja) | 不安障害の治療用及び／又は予防用の医薬組成物 | |
| JP2002515435A (ja) | 鬱病処置のための組合せ治療 | |
| JP2007145875A5 (sh) | ||
| AR035603A1 (es) | Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos | |
| SE0102036D0 (sv) | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof | |
| PL201685B1 (pl) | Zastosowanie N-piperydyno-5-(4-chlorofenylo)-1-(2,4-dichlorofenylo)-4-metylopirazolo-3-karboksyamidu do wytwarzania leków | |
| JP2006507220A5 (sh) | ||
| JP2009541443A5 (sh) | ||
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| JP2008518896A (ja) | ニコチン性アセチルコリンα７受容体アンタゴニストの組合せ剤 | |
| WO2005092307A3 (en) | Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists | |
| EP2301625A3 (en) | Compositions and methods for treating cognitive disorders | |
| WO2006053089A3 (en) | Methods and formulations for making pharmaceutical compositions containing bupropion | |
| JP2002535370A5 (sh) | ||
| JP2004529117A5 (sh) | ||
| CA2483002A1 (en) | New pharmaceutical composition | |
| EP1623741A2 (en) | Cannabinoid receptor ligands for hair growth modulation | |
| WO2005011595A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |